The Immune Contexture of Liposarcoma and Its Clinical Implications
Authors:
- Antonia ResagARAntonia Resag
- Giulia ToffaninGTGiulia Toffanin
- Iva BenešováIBIva Benešová
- Luise MüllerLMLuise Müller
- Vlatko PotkrajcicVPVlatko Potkrajcic
- Andrej OzaniakAOAndrej Ozaniak
- Robert LischkeRLRobert Lischke
- Jirina BartunkovaJBJirina Bartunkova
- Antonio RosatoARAntonio Rosato
- Korinna JöhrensKJKorinna Jöhrens
- Franziska EckertFEFranziska Eckert
- Zuzana StrizovaZuzana Strizova
Open Access
Abstract
Liposarcomas (LPS) are the most frequent malignancies in the soft tissue sarcoma family and consist of five distinctive histological subtypes, termed well-differentiated LPS, dedifferentiated LPS (DDLPS), myxoid LPS (MLPS), pleomorphic LPS, and myxoid pleomorphic LPS. They display variations in genetic alterations, clinical behavior, and prognostic course. While accumulating evidence implicates a crucial role of the tumor immune contexture in shaping the response to anticancer treatments, the immunological landscape of LPS is highly variable across different subtypes. Thus, DDLPS is characterized by a higher abundance of infiltrating T cells, yet the opposite was reported for MLPS. Interestingly, a recent study indicated that the frequency of pre-existing T cells in soft tissue sarcomas has a predictive value for immune checkpoint inhibitor (CPI) therapy. Additionally, B cells and tertiary lymphoid structures were identified as potential biomarkers for the clinical outcome of LPS patients and response to CPI therapy. Furthermore, it was demonstrated that macrophages, predominantly of M2 polarization, are frequently associated with poor prognosis. An improved understanding of the complex LPS immune contexture enables the design and refinement of novel immunotherapeutic approaches. Here, we summarize recent studies focusing on the clinicopathological, genetic, and immunological determinants of LPS.Keywords
Funding Information
- Fondazione AIRC per la ricerca sul cancro ETS (21354, 22759)
- Oncology IOV-IRCCS (BIOV19ROSATO)
- Ministry of Health-Alliance Against Cancer (MoH-ACC) (RCR-2019-23669115)
- Deutsche Krebshilfe (70114187)
This publication has 159 references indexed in Scilit:
- Radiotherapy of Human Sarcoma Promotes an Intratumoral Immune Effector SignatureClinical Cancer Research, 2013
- Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomasBMC Clinical Pathology, 2012
- Copy Number Losses Define Subgroups of Dedifferentiated Liposarcoma with Poor Prognosis and Genomic InstabilityClinical Cancer Research, 2012
- High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicatorOncoImmunology, 2012
- Advances in sarcoma genomics and new therapeutic targetsNature Reviews Cancer, 2011
- Evaluation of well‐differentiated/de‐differentiated liposarcomas by high‐resolution oligonucleotide array‐based comparative genomic hybridizationGenes, Chromosomes and Cancer, 2010
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapyNature Genetics, 2010
- Well-differentiated and dedifferentiated liposarcomasVirchows Archiv, 2009
- Alterations of the RB1 gene in dedifferentiated liposarcomaLaboratory Investigation, 2005
- Cytokine serum levels in soft tissue sarcoma patients: Correlations with clinico‐pathological features and prognosisInternational Journal of Cancer, 2002